×

Biotech and Pharmaceuticals Medicine

  • We remain comfortable with its safety profile, "Jefferies analyst Jeffrey Holford wrote in a client note. "At the time of initial report, both events were considered by the investigator as having no reasonable possibility of being related to the study drug," AbbVie's spokeswoman Jillian Griffin told Reuters. Eli Lilly and Co's rival rheumatoid arthritis drug,...

  • Sept 11- AbbVie Inc said on Monday two patients died in a late-stage trial testing its rheumatoid arthritis drug, raising safety concerns about the drug. In April, the U.S. Food and Drug Administration had declined to approve Eli Lilly and Co's rival drug, baricitinib, calling for an additional clinical study. Three months later, Lilly said the FDA was concerned...

  • Sept 11- AbbVie Inc said on Monday two patients died in a late-stage trial testing its drug to treat patients with moderate to severe rheumatoid arthritis. The company said the reason for one of the deaths is unknown, while the second patient died due to heart failure and presumed pulmonary embolism, or blockage of arteries. AbbVie's shares were down about 1.2...

  • Sept 11- Medical device maker Medtronic Plc said on Monday it would recall certain infusion sets used with its insulin pumps by diabetes patients due to a component that could cause death in extreme cases. Infusion sets help connect an insulin pump device to the body. The Dublin- based company received reports of hypoglycemia requiring medical intervention,...

  • Sept 11- Medtronic Plc on Monday said that it would recall certain infusion sets used with all its insulin pumps due to a discontinued component.

  • MADRID, Sept 11- Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body's defences in the fight against tumours. The latest research shared with 23,000 experts at Europe's top oncology meeting shows how medicines that have already delivered durable benefits in metastatic disease can also work well at an earlier...

  • Sept 11- Janssen Sciences Ireland UC, a unit of Johnson& Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies. Janssen said it would not continue the development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three...

  • PARIS, Sept 11- Sanofi and Regeneron's biotech drug dupilumab scored a hit in treating severe asthma, clinical trial data showed on Monday, raising competition in an expected multibillion-dollar market. Sanofi and Regeneron plan to submit an application to use the medicine in severe asthma to the U.S. Food and Drug Administration by the end of this year.

  • ZURICH/ MADRID, Sept 11- Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53 percent versus placebo in patients...

  • MADRID, Sept 11- Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday. Now results from a large clinical study presented at the European Society for Medical Oncology congress in Madrid show that 71...

  • ROCHE CANCER DRUG ZELBORAF FAILS IN PHASE III ADJUVANT MELANOMA STUDY.

  • NOVARTIS DRUG COMBINATION DOUBLES RELAPSE-FREE SURVIVAL IN MELANOMA PATIENTS AFTER SURGERY- STUDY.

  • NEW YORK/ MADRID, Sept 10- Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent. Experts at the European Society for Medical Oncology congress in Madrid said the experimental drug's efficacy...

  • MADRID, Sept 9- Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July's big clinical trial setback in the disease. Chief Executive Pascal Soriot said it gave AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have made...

  • *Boost for drugmaker's prospects after Mystic trial setback. MADRID, Sept 9- Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July's big clinical trial setback in the disease. Solange Peters of the Centre Hospitalier Universitaire Vaudois in Lausanne, who was not...

  • MADRID, Sept 8- Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair. Research presented at Europe's biggest oncology congress in Madrid adds to evidence that patients with an above average...

  • *Roche and Foundation push new cancer mutation blood test. MADRID, Sept 8- A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumour, potentially helping to predict which patients may respond best to some immunotherapies. Initial data on Roche's test aimed at determining tumour mutational...

  • *Roche and Foundation push new cancer mutation blood test. MADRID, Sept 8- A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumor, potentially helping to predict which patients may respond best to some immunotherapies. Initial data on Roche's test aimed at determining tumor mutational...

  • "We believe the overall survival benefit likely confirms the durability of the signal seen on progression-free survival, leading to a very high likelihood of approval," Leerink Research analyst Seamus Fernandez wrote in a client note. The trials to monitor overall survival rates were to run through the second half of 2019, according to Cowen and Co..

  • The news follows Bristol-Myers Squibb Co's announcement on Wednesday that the FDA had placed similar partial clinical holds on three trials of the company's Opdivo immunotherapy in combination with multiple myeloma treatments. The FDA placed a hold on three Merck multiple myeloma combination trials in July after safety monitors reported more deaths...